# A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

> **NCT03605069** · PHASE1,PHASE2 · TERMINATED · sponsor: **Phoenicis Therapeutics** · enrollment: 2 (actual)

## Conditions studied

- Epidermolysis Bullosa Dystrophica, Recessive
- Epidermolysis Bullosa Dystrophica, Dominant

## Interventions

- **DRUG:** QR-313
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03605069
- **Lead sponsor:** Phoenicis Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-02
- **Primary completion:** 2018-12-17
- **Final completion:** 2018-12-17
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low enrollment
- **Last updated:** 2021-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605069, "A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03605069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*